PATENT CLAIM ANALYSIS

Application Number: 16086717
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["424", "489000"]

Abstract:
The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.

Claim (Index 29):
A reconstituted lyophilized pharmaceutical composition suitable for parenteral administration comprising:\n a 10-100 mg/mL concentration of polymeric nanoparticles in an aqueous medium; wherein the polymeric nanoparticles comprise: a poly(lactic) acid-block-poly(ethylene)glycol copolymer or poly(lactic)-co-poly(glycolic) acid-block-poly(ethylene)glycol copolymer, and a therapeutic agent; about 6 to about 10 weight percent of mannitol; and about 6 to about 9 weight percent of hydroxypropyl \u03b2-cyclodextrin.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 97.0
- Lexical Diversity: 1.14286
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13664133', '15296350', '13916133', '13862090', '13909670']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7961222548663415
- 35 USC 102 Novelty (BERT): 0.5814998662848883
- Combined Prediction Score: 0.7746600160081961
- Mean Citation Score: 488.226772
- Max Citation Score: 495.44614
- Similarity Product: 441.9672907410741

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test